SCOPUS 정보 검색 플랫폼

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 11, 2011, Pages 1254-1255

Endoscopic mucosal healing in ulcerative colitis

(2) Levy, L C a Siegel, C A a

a Dartmouth Hitchcock Inflammatory Bowel Disease Center (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

COLON MUCOSA; COLONOSCOPY; COLORECTAL TUMOR; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; LETTER; MICROSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLONOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL MUCOSA; MESALAMINE; WOUND HEALING;

EID: 79955591192 PISSN: 02692813 EISSN: 13652036 Source Type: Journal
DOI: 10.1111/j.1365-2036.2011.04615.x Document Type: Letter

Times cited : (5)

References (6)

1
- 79951671131
- Randomised clinical trial: Delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND i and II combined analysis
- Lichtenstein GR, Ramsey D, Rubin DT,. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011; 33: 672-8.
- (2011) Aliment Pharmacol Ther , vol.33 , pp. 672-678
- Lichtenstein, G.R.¹ Ramsey, D.² Rubin, D.T.³

2
- 0013969867
- Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets
- Wright R, Truelove SR,. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966; 11: 847-57.
- (1966) Am J Dig Dis , vol.11 , pp. 847-857
- Wright, R.¹ Truelove, S.R.²

3
- 70649110836
- Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
- e1-3
- Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-43, e1-3.
- (2009) Gastroenterology , vol.137 , pp. 1934-1943
- Sandborn, W.J.¹ Regula, J.² Feagan, B.G.³

4
- 34848893583
- Histologic Inflammation Is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort Study
- DOI 10.1053/j.gastro.2007.08.001, PII S0016508507014473
- Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-105. (Pubitemid 47494461)
- (2007) Gastroenterology , vol.133 , Issue.4 , pp. 1099-1105
- Gupta, R.B.¹ Harpaz, N.² Itzkowitz, S.³ Hossain, S.⁴ Matula, S.⁵ Kornbluth, A.⁶ Bodian, C.⁷ Ullman, T.⁸

5
- 10744221150
- Severity of Inflammation Is a Risk Factor for Colorectal Neoplasia in Ulcerative Colitis
- DOI 10.1053/j.gastro.2003.11.010
- Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9. (Pubitemid 38182302)
- (2004) Gastroenterology , vol.126 , Issue.2 , pp. 451-459
- Rutter, M.¹ Saunders, B.² Wilkinson, K.³ Rumbles, S.⁴ Schofield, G.⁵ Kamm, M.⁶ Williams, C.⁷ Price, A.⁸ Talbot, I.⁹ Forbes, A.¹⁰

6
- 0026065160
- Microscopic activity in ulcerative colitis: What does it mean?
- Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME,. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
- (1991) Gut , vol.32 , pp. 174-178
- Riley, S.A.¹ Mani, V.² Goodman, M.J.³ Dutt, S.⁴ Herd, M.E.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.